Safety considerations for erythropoietin treatment in patients with cancer.
Cancer-related anaemia, which affects many patients with cancer, can effectively be treated by erythropoietic proteins. Erythropoietic proteins increase haemoglobin levels, reduce the risk for transfusions and also improve the quality of life of patients. When used according to published practice guidelines, these proteins benefit many patients and are generally well tolerated. Important side effects are hypertension and thromboembolic events, either of which occurs in < 10% of the patients. Administration only in anaemic patients, avoidance of target haemoglobin levels > 130 g/l, proper dose adjustments and close monitoring during treatment will ensure the clinical safety of these proteins. However, the association between erythropoietic proteins and outcome of anticancer therapy, including survival, requires further study.
Pirker
Robert
R
Lung Cancer, Medical University of Vienna, Department of Internal Medicine I, Währinger Gürtel 18-20, A-1090 Vienna, Austria. robert.pirker@meduniwien.ac.at
D004921:Erythropoietin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D011994:Recombinant Proteins; D015996:Survival Rate
D011994:Recombinant Proteins; D004921:Erythropoietin